HKSE · 2563.HK
Beijing Biostar Pharms Co Ltd
HK$3.40-HK$0.15 (-4.23%)
Beijing Biostar Pharms Co Ltd’s quoted price sits in the lower half of its reported 52-week range, 35.24% below the high.
Loading market information…
HKSE · 8037.HK · HKD
Stock price, dividends, earnings
Quote as of Oct 27, 2026, 05:56 AM UTC. Cached market data; not a live quote.
One-year closing-price history · HKD. Historical prices are not a forecast.
China Biotech Services Holdings Limited’s quoted price sits in the lower half of its reported 52-week range, 54.81% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow China Biotech Services Holdings Limited’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Established in 1996 and based in Causeway Bay, Hong Kong, China Biotech Services Holdings Limited functions as an investment holding company. Its core business involves providing medical laboratory testing and health check services throughout mainland China and Hong Kong. The company organizes its varied operations into five main divisions: Immunotherapy, Pharmaceutical Products, Medical and Health Related Services, Securities, and Insurance Brokerage, in addition to other undertakings. Its comprehensive activities include the research, development, manufacturing, and sale of both health-related and pharmaceutical products. The company also offers specialized medical services, such as tumor immune cell therapy, immune cell storage, and health management programs, alongside coordinating healthcare providers. Furthermore, it participates in financial services like securities trading, money lending, and providing insurance brokerage. Its commercial ventures also extend to marketing and distributing a range of wellness products, including health supplements, slimming aids, traditional Chinese medicines, and beauty products, as well as trading pharmaceutical intermediates. Property investment and logistics services round out its operational scope. The company transitioned to its current name in November 2017, having previously been known as Rui Kang Pharmaceutical Group Investments Limited.
Latest available per-share figures in HKD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 07:57 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
HK$3.40-HK$0.15 (-4.23%)
Beijing Biostar Pharms Co Ltd’s quoted price sits in the lower half of its reported 52-week range, 35.24% below the high.
HK$11.10+HK$0.10 (+0.91%)
Wenzhou Kangning Hospital Co., Ltd.’s quoted price sits in the upper half of its reported 52-week range, 5.13% below the high.
HK$1.77-HK$0.01 (-0.56%)
CANbridge Pharmaceuticals Inc.’s quoted price sits in the lower half of its reported 52-week range, 49.43% below the high.
HK$2.37-HK$0.12 (-4.63%)
Pak Fah Yeow International Limited’s quoted price sits in the lower half of its reported 52-week range, 13.19% below the high.
HK$1.32-HK$0.12 (-8.33%)
Kintor Pharmaceutical Limited’s quoted price sits in the lower half of its reported 52-week range, 71.91% below the high.
HK$3.39-HK$0.02 (-0.44%)
Hospital Corporation of China Limited’s quoted price sits in the lower half of its reported 52-week range, 50.8% below the high.
HK$0.06-HK$0.00 (-1.54%)
Uni-Bio Science Group Limited’s quoted price sits in the lower half of its reported 52-week range, 61.9% below the high.
HK$1.39+HK$0.01 (+0.72%)
Suzhou Basecare Medical Corporation Limited’s quoted price sits in the lower half of its reported 52-week range, 47.55% below the high.
